118 related articles for article (PubMed ID: 32964980)
1. LPAR5 stimulates the malignant progression of non-small-cell lung carcinoma by upregulating MLLT11.
Zhang HP; Chen QK; Xu JF
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8902-8910. PubMed ID: 32964980
[TBL] [Abstract][Full Text] [Related]
2. Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5.
Zheng YQ; Miao X; Li J; Hu MF; Zhu YS; Li XR; Zhang YJ
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6417-6425. PubMed ID: 32572939
[TBL] [Abstract][Full Text] [Related]
3. MiR-587 acts as an oncogene in non-small-cell lung carcinoma via reducing CYLD expression.
Li XJ; Chen LW; Gao P; Jia YJ
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12741-12747. PubMed ID: 33378022
[TBL] [Abstract][Full Text] [Related]
4. MAGI1-IT1 stimulates proliferation in non-small cell lung cancer by upregulating AKT1 as a ceRNA.
Zhang G; Chen HX; Yang SN; Zhao J
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):691-698. PubMed ID: 32016970
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.
Qiu HB; Yang K; Yu HY; Liu M
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569
[TBL] [Abstract][Full Text] [Related]
6. SRPX2 promotes cell proliferation and invasion via activating FAK/SRC/ERK pathway in non-small cell lung cancer.
Li X; Liu J; Sun H; Zou Y; Chen J; Chen Y; Chen C; Wu X
Acta Biochim Pol; 2020 Jun; 67(2):165-172. PubMed ID: 32550700
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-19a promotes proliferative and migratory abilities of NSCLC cells by inhibiting PTEN expression.
Shi J; Han Y; Lin D; Wang K; Liu B; Gao C
J BUON; 2019; 24(3):955-962. PubMed ID: 31424647
[TBL] [Abstract][Full Text] [Related]
8. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
9. MiRNA-621 inhibits the malignant progression of non-small cell lung cancer via targeting SIX4.
Zhang M; Shi H; Zhang C; Zhang SQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4807-4814. PubMed ID: 31210312
[TBL] [Abstract][Full Text] [Related]
10. CircRNF20 aggravates the progression of non-small-cell lung carcinoma by activating MAPK9.
Wang ZX; Zhao Y; Wang YB; Zhang Q; Zou QX; Liang FH; Lin FW
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9981-9989. PubMed ID: 33090403
[TBL] [Abstract][Full Text] [Related]
11. LncRNA HANR aggravates the progression of non-small cell lung cancer via mediating miRNA-140-5p.
Li SJ; Wu YX; Liang YH; Gao Y; Wu AB; Zheng HY; Yang ZX
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):704-711. PubMed ID: 32016972
[TBL] [Abstract][Full Text] [Related]
12. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.
Zhu FY; Zhang SR; Wang LH; Wu WD; Zhao H
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8377-8390. PubMed ID: 31646568
[TBL] [Abstract][Full Text] [Related]
13. MiRNA-200a-3p suppresses the proliferation, migration and invasion of non-small cell lung cancer through targeting IRS2.
Tan T; Xu XH; Lu XH; Wang XW
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):712-720. PubMed ID: 32016973
[TBL] [Abstract][Full Text] [Related]
14. LncRNA AWPPH accelerates the progression of non-small cell lung cancer by sponging miRNA-204 to upregulate CDK6.
Wu D; Qin BY; Qi XG; Hong LL; Zhong HB; Huang JY
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4281-4287. PubMed ID: 32373964
[TBL] [Abstract][Full Text] [Related]
15. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
[TBL] [Abstract][Full Text] [Related]
16. TM4SF1 facilitates non-small cell lung cancer progression through regulating YAP-TEAD pathway.
Fu XY; Zhou WB; Xu J
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1829-1840. PubMed ID: 32141552
[TBL] [Abstract][Full Text] [Related]
17. JMJD3 enhances invasiveness and migratory capacity of non-small cell lung cancer cell via activating EMT signaling pathway.
Zhang Y; Hua PY; Jin CY; Li JD; Zhang GX; Wang B
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4784-4792. PubMed ID: 31210309
[TBL] [Abstract][Full Text] [Related]
18. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4.
Liao XH; Wang Y; Zhong B; Zhu SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3143-3151. PubMed ID: 32271432
[TBL] [Abstract][Full Text] [Related]
19. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
[TBL] [Abstract][Full Text] [Related]
20. RBBP6 aggravates the progression of ovarian cancer by targeting PIK3R6.
Liu YJ; Cui LL; Liu ZS; Jia RY; Ding YX; Xu LZ
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10366-10374. PubMed ID: 33155192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
